Poster: CT-227 Dual CAR-Engineered NK92 Cells: An Off-the-Shelf Cell Therapy for Cancer

The robust ex vivo expansion of NK92 cells and their exquisite safety profile, as well as the ease of genetic modification, make this cell line an ideal platform for the development of an off-the-shelf therapeutic CAR-engineered variant to target other tumors. Overall, CAR NK-92 cells can be produced at much lower cost compared to CAR T cells and will be a ready-to-use drug, immediately available for cancer patients, with a significant implication for their survival.